Huber Needles Market Projected to Exhibit 1.6X Growth by 2024

(Newswire.net — June 21, 2017) New York City, New York — Emergence of modern healthcare has altered complete demography of healthcare tools market. Huber needle is among such tools for treating cancer patients. With prevailing diseases such as obesity, chronic renal ailments and cancer, Huber needles industry has witnessed a surge over the past few years. Persistence Market Research (PMR), in its report estimates impressive growth for global Huber needles market throughout the forecast period 2016 to 2024. In terms of revenue, the market is projected to witness 1.6X growth through 2024.

Factors Influencing Growth of Global Huber Needles Market Include

• Surging prevalence of blood-related diseases and chronic diseases such as renal diseases and cancer
• Increasing awareness of Huber needles among patients
• Growing number of government initiatives for utilisation of safety needles
• Increasing disposable income of people across the globe
• Requirement of effective chronic disease management associated with long-term drug infusion and medication
• Rising prevalence of safety Huber needles on the back of their convenience and benefits
• Increasing investments in research & development activities
• Introduction of novel products

In contrast, comparatively high prices of Huber needles than conventional needles, contamination risks, and absence of product innovation are some factors identified by PMR’s report to restrain market growth during the forecast period.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3291

Some key market players identified in the report include Baxter International, Inc., NIPRO Medical Corporation, Smiths Medical, Vygon S.A., C.R. Bard, B. Braun Medical, Inc., Exel International, Inc., AngioDynamics, Inc., and Thiebaud S.A.S. PMR’s report sheds light on short-term and long-term company strategies, recent developments, and key offerings in the market. Few of the aforementioned companies are shifting toward adoption of distribution agreement as key strategy for expanding their global presence.

North America to be the Largest Market for Huber Needles by 2024-End

North America is estimated to be dominant in the global market for Huber needles by 2024-end. This is attributed to increasing Huber needles adoption for the purpose of long-term drug infusion therapies including dialysis and chemotherapy, and high diagnosis rate in this region. Market in Asia Pacific (APAC) is projected to exhibit highest CAGR during the forecast period. Some key factors such as substantial rise in healthcare services spending coupled with growing awareness about health issues and rapid economic growth are estimated to propel market growth in APAC by 2024.

Global Huber needles market is bifurcated into curved Huber needles and straight Huber needles based on product type. Curved Huber needles have been witnessing a wide adoption in dialysis, blood transfusion and drug infusion. Demand for curved Huber needles is estimated to expand at 6.3% CAGR during the forecast period.

View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/huber-needle-market/toc

IV Cancer Application to Register Highest Adoption of Huber Needles by 2024

By application, the market is categorised into home parenteral nutrition, lap band adjustments, IV cancer application, blood transfusions, and dialysis. Adoption of Huber needles in IV cancer application is expected to remain highest during the forecast period. In addition, demand for Huber needles in blood transfusion is estimated to witness fastest expansion at 6.2% CAGR through 2024.

Based on end-users, the market is categorised into home care settings, ambulatory surgical centres, clinics, oncology centres, and hospitals. Hospitals will account for highest adoption of Huber needles by 2024-end. Demand for Huber needles by hospital is pegged to surpass US$ 20 million in revenues by 2024. In addition, oncology clinics held more than one-fourth of market share in 2016.